[1]叶治莲,郭晓兰,HUSSAIN KAMAL(巴基斯坦),等.巨噬细胞异质性在慢性阻塞性肺疾病中的研究进展[J].陕西医学杂志,2026,(7):991-995.[doi:DOI:10.3969/j.issn.1000-7377.2026.07.021]
点击复制

巨噬细胞异质性在慢性阻塞性肺疾病中的研究进展

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
期数:
2026年7期
页码:
991-995
栏目:
综述
出版日期:
2026-07-05

文章信息/Info

作者:
叶治莲1郭晓兰2HUSSAIN KAMAL3(巴基斯坦)章倩倩1
(1.广东药科大学基础医学院,广东 广州510006;2.广州医科大学 中国科学院广州生物医药与健康研究院联合生命科学学院,广东 广州511436;3.广州医科大学国际教育学院,广东 广州511436)
关键词:
慢性阻塞性肺疾病巨噬细胞异质性气道重塑表观遗传靶向治疗
分类号:
R 563
DOI:
DOI:10.3969/j.issn.1000-7377.2026.07.021
文献标志码:
A
摘要:
慢性阻塞性肺疾病(COPD)患病率高、危害性大,尚无有效治疗策略,因其疾病进程呈现高度的动态复杂性,尚未完全阐明其机制。巨噬细胞作为呼吸道最重要的先天免疫细胞,在病原清除、炎症调控和组织重塑中发挥关键作用。解析其异质性和功能分化,对理解不断演变的内在病理机制,具有重要作用。近年来,单细胞组学和空间转录组技术发现,COPD肺内存在来源不同、表型各异的巨噬细胞分型,它们在炎症放大、小气道重塑和肺气肿病理进程发挥不同功能。本综述围绕巨噬细胞异质性,从来源谱系、功能亚群及空间分布三个维度,系统梳理巨噬细胞异质性在COPD不同疾病阶段和临床表型中的作用,旨在通过靶向特定巨噬细胞亚群的干预策略,为COPD的精准治疗提供新的理论基础和干预靶点。

参考文献/References:

[1]BOUCHERAT O,MORISSETTE M C,PROVENCHER S,et al.Bridging lung development with chronic obstructive pulmonary disease.Relevance of developmental pathways in chronic obstructive pulmonary disease pathogenesis[J].Am J Respir Crit Care Med,2016,193(4):362-375.
[2]BOERS E,BARRETT M,SU J G,et al.Global burden of chronic obstructive pulmonary disease through 2050[J].JAMA Netw Open,2023,6(12):e2346598.
[3]AGUSTí A,CELLI B R,CRINER G J,et al.Global initiative for chronic obstructive lung disease 2023 report:GOLD executive summary[J].Am J Respir Crit Care Med,2023,207(7):819-837.
[4]WU J,ZHAO X,XIAO C,et al.The role of lung macrophages in chronic obstructive pulmonary disease[J].Respir Med,2022,205:107035.
[5]XUE J,SCHMIDT S V,SANDER J,et al.Transcriptome-based network analysis reveals a spectrum model of human macrophage activation[J].Immunity,2014,40(2):274-288.
[6]YUNNA C,MENGRU H,LEI W,et al.Macrophage M1/M2 polarization[J].Eur J Pharmacol,2020,877:173090.
[7]ROCHA N N,DE OLIVEIRA M V,BRAGA C L,et al.Ghrelin therapy improves lung and cardiovascular function in experimental emphysema[J].Respir Res,2017,18(1):185.
[8]UCHIYAMA R,TOYODA E,MAEHARA M,et al.Effect of platelet-rich plasma on M1/M2 macrophage polarization[J].Int J Mol Sci,2021,22(5):2336.
[9]XIAO T,ZOU Z,XUE J,et al.LncRNA H19-mediated M2 polarization of macrophages promotes myofibroblast differentiation in pulmonary fibrosis induced by arsenic exposure[J].Environ Pollut,2021,268(Pt A):115810.
[10]TAKIGUCHI H,YANG C X,YANG C W T,et al.Macrophages with reduced expressions of classical M1 and M2 surface markers in human bronchoalveolar lavage fluid exhibit pro-inflammatory gene signatures[J].Sci Rep,2021,11(1):8282.
[11]LU Y,DENG M,YIN Y,et al.Global trends in research regarding macrophages associated with chronic obstructive pulmonary disease:A bibliometric analysis from 2011 to 2022[J].Int J Chron Obstruct Pulmon Dis,2023,18:2163-2177.
[12]周子程,张润峰.巨噬细胞在心肌梗死中的作用研究进展[J].陕西医学杂志,2024,53(5):714-717.
[13]HU Y,SHAO X,XING L,et al.Single-cell sequencing of lung macrophages and monocytes reveals novel therapeutic targets in COPD[J].Cells,2023,12(24):2771.
[14]LIéGEOIS M,BAI Q,FIEVEZ L,et al.Airway macrophages encompass transcriptionally and functionally distinct subsets altered by smoking[J].Am J Respir Cell Mol Biol,2022,67(2):241-252.
[15]HOU F,XIAO K,TANG L,et al.Diversity of macrophages in lung homeostasis and diseases[J].Front Immunol,2021,12:753940.
[16]WOHNHAAS C T,BABLER K,WATSON C K,et al.Monocyte-derived alveolar macrophages are key drivers of smoke-induced lung inflammation and tissue remodeling[J].Front Immunol,2024,15:1325090.
[17]ZIEGLER-HEITBROCK L,ANCUTA P,CROWE S,et al.Nomenclature of monocytes and dendritic cells in blood[J].Blood,2010,116(16):e74-e80.
[18]DESCH A N,GIBBINGS S L,GOYAL R,et al.Flow cytometric analysis of mononuclear phagocytes in nondiseased human lung and lung-draining lymph nodes[J].Am J Respir Crit Care Med,2016,193(6):614-626.
[19]PARAJULI N,SUBEDI K,SOLONE X K,et al.Epigenetic control of alveolar macrophages:Impact on lung health and disease[J].Cells,2025,14(9):640.
[20]VERWAERDE S,HASTIR J F,SCHETTERS S T T,et al.Innate type 2 lymphocytes trigger an inflammatory switch in alveolar macrophages[J].Immunity,2025,59(1):60-78.e9.
[21]CAKAROVA L,MARSH L M,WILHELM J,et al.Macrophage tumor necrosis factor-alpha induces epithelial expression of granulocyte-macrophage colony-stimulating factor:Impact on alveolar epithelial repair[J].Am J Respir Crit Care Med,2009,180(6):521-532.
[22]GUO X,YANG S,ZHU H,et al.Involvement of M2 macrophages polarization in PM2.5-induced COPD by upregulating MMP12 via IL4/STAT6 pathway[J].Ecotoxicol Environ Saf,2024,283:116793.
[23]WANG C,HYAMS B,ALLEN N C,et al.Dysregulated lung stroma drives emphysema exacerbation by potentiating resident lymphocytes to suppress an epithelial stem cell reservoir[J].Immunity,2023,56(3):576-591.e10.
[24]CHAKAROV S,LIM H Y,TAN L,et al.Two distinct interstitial macrophage populations coexist across tissues in specific subtissular niches[J].Science,2019,363(6432):eaau0964.
[25]GUILLIAMS M,DE KLEER I,HENRI S,et al.Alveolar macrophages develop from fetal monocytes that differentiate into long-lived cells in the first week of life via GM-CSF[J].J Exp Med,2013,210(10):1977-1992.

[26]GIBBINGS S L,THOMAS S M,ATIF S M,et al.Three unique interstitial macrophages in the murine lung at steady state[J].Am J Respir Cell Mol Biol,2017,57(1):66-76.
[27]DEWHURST J A,LEA S,HARDAKER E,et al.Characterisation of lung macrophage subpopulations in COPD patients and controls[J].Sci Rep,2017,7(1):7143.
[28]LI S,JIANG L,YANG Y,et al.Siglec1 enhances inflammation through miR-1260-dependent degradation of IκBα in COPD[J].Exp Mol Pathol,2020,113:104398.
[29]TANNO A,FUJINO N,YAMADA M,et al.Decreased expression of a phagocytic receptor Siglec-1 on alveolar macrophages in chronic obstructive pulmonary disease[J].Respir Res,2020,21(1):30.
[30]SAITO T,FUJINO N,KYOGOKU Y,et al.Identification of siglec-1-negative alveolar macrophages with proinflammatory phenotypes in chronic obstructive pulmonary disease[J].Am J Physiol Lung Cell Mol Physiol,2024,326(6):1672-1686.

[31]ZHOU L,WANG M,GUO H,et al.Integrated analysis highlights the immunosuppressive role of TREM2(+) macrophages in hepatocellular carcinoma[J].Front Immunol,2022,13:848367.
[32]ZHU Y,CHOI D,SOMANATH P R,et al.Lipid-laden macrophages in pulmonary diseases[J].Cells,2024,13(11):889.

[33]WEEN M P,WHITE J B,TRAN H B,et al.The role of oxidised self-lipids and alveolar macrophage CD1b expression in COPD[J].Sci Rep,2021,11(1):4106.
[34]HSIEH M H,LAI P F,CHEN P C,et al.Exosomal microrna let-7 modulates lipid metabolism and inflammation in foamy macrophages of chronic obstructive pulmonary disease[J].Int J Mol Sci,2025,26(18):8800.

[35]HE S,TIAN R,ZHANG X,et al.PPARγ inhibits small airway remodeling through mediating the polarization homeostasis of alveolar macrophages in COPD[J].Clin Immunol,2023,250:109293.

相似文献/References:

[1]马明铭,李 芳,杨 慧,等.噻托溴胺粉雾剂联合非药物康复方案对慢性阻塞性肺疾病患者BODE指数的影响[J].陕西医学杂志,2019,(4):515.
 MA Mingming,LI Fang,YANG Hui,et al.Effect of tiotropium bromide powder and nonpharmacological rehabilitation program on BODE index in patients with chronic obstructive pulmonary disease[J].,2019,(7):515.
[2]朱小川.血小板/淋巴细胞比值预测慢性阻塞性肺疾病急性加重期〖JZ〗伴有早期肾功能损害临床价值[J].陕西医学杂志,2019,(10):1353.
 ZHU Xiaochuan..Clinical value of platelet/lymphocyte ratio in predicting early renal impairment〖JZ〗 in acute exacerbation of chronic obstructive pulmonary disease[J].,2019,(7):1353.
[3]张军营.吸烟对慢阻肺患者血清S100A8/A9、8异前列腺素F2α、组织蛋白酶S及其它炎症因子表达水平的影响*[J].陕西医学杂志,2019,(11):1426.
[4]焦文妤,尚家璐,李树霞△.慢性阻塞性肺疾病患者血清补体C1q肿瘤坏死因子相关蛋白5与肺功能及炎症反应相关性研究[J].陕西医学杂志,2019,(12):1616.
[5]陈辅萍.慢性阻塞性肺疾病并发感染性肺炎危险因素分析[J].陕西医学杂志,2020,49(1):102.
[6]薛佩妮,冯敏娟△,王惠琴.噻托溴铵粉联合糖皮质激素治疗慢性阻塞性肺疾病疗效及对患者生活质量评分的影响*[J].陕西医学杂志,2020,49(2):216.
 XUE Peini,FENG Minjuan,WANG Huiqin..Efficacy of tiotropium bromide combined with glucocorticoids in the treatment of COPD and its effect on patients' quality of life score[J].,2020,49(7):216.
[7]焦文妤,高爱华△.血清可溶性髓系细胞触发受体-1与临床肺部感染评分在慢性阻塞性肺疾病呼吸机相关性肺炎早期诊断及预后判断中的效能研究[J].陕西医学杂志,2020,49(12):1630.[doi:DOI:10.3969/j.issn.1000-7377.2020.12.024]
 JIAO Wenyu,GAO Aihua..Effectiveness of sTREM-1 and CPIS in early diagnosis and prognosis judgment of ventilator-associated pneumonia in COPD[J].,2020,49(7):1630.[doi:DOI:10.3969/j.issn.1000-7377.2020.12.024]
[8]张卓红,赵拖利.慢性阻塞性肺疾病大鼠血液、支气管灌洗液中水通道蛋白及p-c-Jun-N-末端激酶表达情况实验研究[J].陕西医学杂志,2021,50(7):776.[doi:DOI:10.3969/j.issn.1000-7377.2021.07.002]
 ZHANG Zhuohong,ZHAO Tuoli.Expression of AQP-1 and p-JNK in blood and bronchial lavage fluid of rats with COPD[J].,2021,50(7):776.[doi:DOI:10.3969/j.issn.1000-7377.2021.07.002]
[9]余 刚,张飔雪.慢性阻塞性肺疾病急性加重期患者血清干扰素-γ、甲壳质酶蛋白-40水平及与预后、肺功能相关性分析[J].陕西医学杂志,2021,50(10):1223.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.011]
 YU Gang,ZHANG Sixue.The levels of INF-γ and YKL-40 in patients with AECOPD and their correlation with prognosis and lung function[J].,2021,50(7):1223.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.011]
[10]曾德优,张六一,肖 创,等.慢性阻塞性肺疾病动物模型研究进展[J].陕西医学杂志,2022,51(4):507.[doi:DOI:10.3969/j.issn.1000-7377.2022.04.029]
 ZENG Deyou,ZHANG Liuyi,XIAO Chuang,et al.Research progress on animal models of chronic obstructive pulmonary disease[J].,2022,51(7):507.[doi:DOI:10.3969/j.issn.1000-7377.2022.04.029]

备注/Memo

备注/Memo:
国家自然科学基金资助青年项目(82300056)
更新日期/Last Update: 2026-07-10